De Lucia Orazio, Giarda Federico, Bernetti Andrea, Ceccarelli Chiara, Mauro Giulia Letizia, Gervasoni Fabrizio, Berti Lisa, Robecchi Majnardi Antonio
Clinical Rheumatology Unit, Department of Rheumatology and Medical Sciences, ASST Centro Traumatologico Ortopedico G. Pini-CTO, 20122 Milan, Italy.
Unit of Rehabilitation Medicine and Neurorehabilitation, Department of Neuroscience, ASST Niguarda Hospital, 20162 Milan, Italy.
J Clin Med. 2025 Aug 27;14(17):6058. doi: 10.3390/jcm14176058.
BACKGROUND/OBJECTIVES: Musculoskeletal disorders causing chronic pain are increasingly prevalent due to factors such as injury, overuse, and aging, leading to interest in porcine collagen injections as a potential therapeutic and conservative option. Despite promising results, evidence-based information on this treatment is scarce. To address this gap, the authors conducted an eDelphi consensus among expert Italian physicians in musculoskeletal pain to gather their perspectives on collagen injections.
A Steering Committee and a Panel of 23 physicians developed the statements list (36) including the modalities, safety, and efficacy of intra- and extra-articular collagen injections. Panelists rated their agreement with each statement on a 5-point Likert scale (5 means "Strong Agreement"). Consensus was defined as when at least 75% of the panelists voted with a score of ≥4/5 after two rounds of votes. The weighted average (WA) was calculated for each statement. As control, we elaborated a Hypothetical Parametric Distribution (HPD WA equal to 3.00), where the percent of panelists is equally distributed along each Likert Scale Value (LSV). The maximum WA for 75% of the consensus is established at 3.75. Indeed, the combination of 75% having WA > 3.75 was defined as "Strong Agreement". While, if the consensus was under 75%, the WA vs. HPD comparison was performed using the Wilcoxon Test. Significant differences among the distribution of LSVs judged the statement as "Low Level of Agreement". Disagreement was evaluated when the WA was under the PHD.
The consensus was reached "Strong Agreement" after twin rounds in 29 out of 36 (8.55%). In 5 out of 36 statements (13.89%), the panelists reached the "Low Level of Agreement" by statistical tests. In the remaining two statements, there was a "Consensus of Disagreement". All panelists unanimously agreed on crucial points, such as contraindications, non-contraindication based solely on comorbidity, and the importance of monitoring collagen's effectiveness. Unanimous agreement was reached on recommending ultrasound guidance and associating collagen injections with therapeutic exercise and physical modalities. Substantial consensus (concordance > 90%) supported collagen injections for osteoarthritis, chondropathy, and degenerative tendinopathies, emphasizing intra- and peri-articular treatment, even simultaneously. However, areas with limited evidence, such as the combination of collagen with other injectable drugs, treatment of myofascial syndrome, and injection frequency, showed disagreement. The potential of intra-tendinous porcine collagen injections for tendon regeneration yielded mixed results.
Clinicians experts in musculoskeletal pain agree on using collagen injections to treat pain originating from joints (e.g., osteoarthritis) and periarticular (e.g., tendinopathies).
背景/目的:由于受伤、过度使用和衰老等因素,导致慢性疼痛的肌肉骨骼疾病日益普遍,这引发了人们对猪胶原蛋白注射作为一种潜在治疗和保守选择的兴趣。尽管取得了令人鼓舞的结果,但关于这种治疗的循证信息却很少。为了填补这一空白,作者在意大利肌肉骨骼疼痛领域的专家医生中进行了一项电子德尔菲共识调查,以收集他们对胶原蛋白注射的看法。
一个指导委员会和一个由23名医生组成的小组制定了陈述列表(共36条),内容包括关节内和关节外胶原蛋白注射的方式、安全性和有效性。小组成员用5级李克特量表对每条陈述表示同意程度(5表示“强烈同意”)。两轮投票后,至少75%的小组成员投票得分≥4/5被定义为达成共识。计算每条陈述的加权平均值(WA)。作为对照,我们构建了一个假设参数分布(HPD WA等于3.00),其中小组成员的百分比沿每个李克特量表值(LSV)均匀分布。75%达成共识的最大WA设定为3.75。实际上,75%的人WA>3.75的组合被定义为“强烈同意”。而如果共识低于75%,则使用威尔科克森检验对WA与HPD进行比较。LSV分布之间的显著差异将该陈述判定为“低同意程度”。当WA低于PHD时评估存在分歧。
36条陈述中有29条(8.55%)在两轮投票后达成了“强烈同意”。36条陈述中有5条(13.89%)通过统计检验小组成员达成了“低同意程度”。在其余两条陈述中,存在“分歧共识”。所有小组成员在关键问题上一致同意,如禁忌症、不能仅基于合并症作为非禁忌症以及监测胶原蛋白有效性的重要性。在推荐超声引导以及将胶原蛋白注射与治疗性运动和物理治疗方法相结合方面达成了一致意见。对于骨关节炎、软骨病和退行性肌腱病进行胶原蛋白注射获得了实质性共识(一致性>90%),强调关节内和关节周围治疗,甚至可以同时进行。然而,在证据有限的领域,如胶原蛋白与其他注射药物的联合使用、肌筋膜综合征的治疗以及注射频率,存在分歧。猪胶原蛋白肌腱内注射促进肌腱再生的潜力结果不一。
肌肉骨骼疼痛领域的临床专家一致同意使用胶原蛋白注射来治疗源自关节(如骨关节炎)和关节周围(如肌腱病)的疼痛。